NCT00350051 - ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2006

Primary Completion Date

September 24, 2008

Study Completion Date

December 21, 2009

Conditions

Prostate Cancer

Interventions

DRUG

Sagopilone (ZK 219477) + prednisone

Chemotherapy for hormone refractory prostate cancer; 16mg/m2 (up to 32mg/m2 max) IV on day 1 or each 21 day cycle for 6 cycles or until progression or unacceptable toxicity.

Trial Locations (17)

1406

Buenos Aires

10469

The Bronx

16601

Altoona

21201

Baltimore

34237

Sarasota

44718

Canton

48109

Ann Arbor

59101

Billings

76104

Fort Worth

92708

Fountain Valley

97201

Portland

68198-7680

Omaha

98108-1597

Seattle

C1280AEB

Buenos Aires

C1405DCS

Buenos Aires

C1416CRJ

Buenos Aires

X5016KEH

Córdoba